Posted by Michael Wonder on 31 Jul 2020
NICE recommends Bavencio (avelumab) in combination with axitinib for first-line treatment of adult patients with advanced renal cell carcinoma
31 July 2020 - This is the first combination of an immunotherapy with a targeted antiangiogenic therapy to be recommended by NICE as a first-line treatment option for advanced renal cell carcinoma for use within the Cancer Drugs Fund.
Merck and Pfizer announced today that the National Institute for Health and Care Excellence has recommended the immunotherapy Bavencio (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma for use within the Cancer Drugs Fund.
